Indo US Bio-Tech Ratios

Indo US Bio-Tech Ltd Ratios

The Indo US Bio-Tech Ltd Ratios page provides a complete fundamental analysis of Indo US Bio-Tech Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Indo US Bio-Tech Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Indo US Bio-Tech Ltd (NSE: INDOUS, BSE: 541304) is currently trading at ₹99.85, with a market capitalization of ₹2.02B. As a major player in the Process industries sector and Agricultural commodities/Milling industry, Indo US Bio-Tech Ltd remains a key stock for fundamental analysis using Indo US Bio-Tech Ltd Ratios.

Indo US Bio-Tech Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Indo US Bio-Tech Ltd P/E ratio currently stands at 18.15, making it one of the most tracked metrics in Indo US Bio-Tech Ltd Ratios.

Historically, the Indo US Bio-Tech Ltd P/E ratio has shown strong fluctuations:

• 2024: 18.15
• 2023: 54.01
• 2022: 28.31
• 2021: 7.89
• 2018: 23.62

The decline in Indo US Bio-Tech Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Indo US Bio-Tech Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 3.76.

Historical P/B trend:

• 2024: 3.76
• 2023: 7.09
• 2022: 3.91
• 2021: 1.59

Indo US Bio-Tech Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Indo US Bio-Tech Ltd P/S ratio currently stands at 2.84, an important part of Indo US Bio-Tech Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 2.84
• 2023: 6.11
• 2022: 3.32
• 2021: 0.83

A stable or declining Indo US Bio-Tech Ltd P/S ratio indicates cautious market sentiment.

Indo US Bio-Tech Ltd Price to Cash Flow Ratio (P/CF)

The Indo US Bio-Tech Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 378550.

Historical Indo US Bio-Tech Ltd Price to Cash Flow Ratio:

• 2024: 378550
• 2023: 615.12
• 2022: 0
• 2021: 23.81
• 2018: 0

The rising Indo US Bio-Tech Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Indo US Bio-Tech Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Indo US Bio-Tech Ltd EV currently stands at ₹3.1B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 3.1B
• 2023: 4.58B
• 2022: 2.16B
• 2021: 537.61M

Indo US Bio-Tech Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Indo US Bio-Tech Ltd EV/EBITDA ratio is currently 16.22, a key metric in Indo US Bio-Tech Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 16.22
• 2023: 41.97
• 2022: 23.03
• 2021: 7.74

Stable Indo US Bio-Tech Ltd EV/EBITDA indicates balanced valuation.

Indo US Bio-Tech Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Indo US Bio-Tech Ltd D/E ratio is currently 0.19, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.19
• 2023: 0.23
• 2022: 0.21
• 2021: 0.32

Indo US Bio-Tech Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Indo US Bio-Tech Ltd ROE currently stands at 23.03%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 23.03
• 2023: 14.06
• 2022: 15.57
• 2021: 0

Indo US Bio-Tech Ltd demonstrates strong profitability and efficient capital utilization.

Indo US Bio-Tech Ltd Ratios Analysis Summary

The Indo US Bio-Tech Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Indo US Bio-Tech Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Indo US Bio-Tech Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.